Search Results for "Neupro"

21:01 EDT 24th August 2016 | BioPortfolio

Matching Channels


Matching News

BRIEF-UCB posts FY REBIT ahead of Reuters poll

* FY revenue and net sales increased driven by product growth: Cimzia, Vimpat, Neupro and Keppra combined reached net sales of 2.76 billion euros ($3.05 billion) (+29 pct); representing 77 pct of net...

US court rules in favour of UCB in patent dispute, shares jump

UCB has received a major boost after a Delaware district court confirmed the validity of the company’s patents on one of its major drugs, the anti-seizure drug Vimpat (lacosamide). The court decisio...

Cimzia and epilepsy drugs fuel UCB growth

Strong performances from its flagship products have lifted revenues of specialist pharma company UCB.The Belgium-headquartered firm announced its 2015 results late last week, with reven...

Parkinson's Disease Market Will Exceed $3 Billion by 2021 Despite Little Advance Towards a Cure, Says GBI Research

LONDON, February 25, 2016 /PRNewswire/ -- A new report from business intelligence provider GBI Research - Parkinson's Disease Therapeutics in Major Developed Markets to 2021 - states that the Parkins...

Parkinson's Diseases: World Drug Industry and Market 2016-2026

LONDON, June 1, 2016 /PRNewswire/ -- Parkinson's Diseases: World Drug Industry and Market 2016-2026 - Our New Study Reveals Trends, R&D Progress, and Predicted Revenues Our new report discusses ...

Matching PubMed Articles

Clinical Pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.

Restless legs syndrome/Willis Ekbom disease (RLS/WED) is a sensorimotor disorder characterized by unpleasant sensations in the legs accompanied by an urge to move them, that typically occurs and tend ...

Search Whole site using Google

Quick Search
Advertisement Advertisement